

Accepted Manuscript

Expression profile of key immune-related genes in *Penaeus monodon* juveniles after oral administration of recombinant envelope protein VP28 of white spot syndrome virus

Ancy Thomas, Naduvilamuriparampu Saidumammed Sudheer, Viswanath Kiron, Issac S. Bright Singh, Rangarajan Badri Narayanan

PII: S0882-4010(15)30064-4

DOI: [10.1016/j.micpath.2016.05.002](https://doi.org/10.1016/j.micpath.2016.05.002)

Reference: YMPAT 1826

To appear in: *Microbial Pathogenesis*

Received Date: 5 August 2015


Revised Date: 28 April 2016

Accepted Date: 2 May 2016

Please cite this article as: Thomas A, Sudheer NS, Kiron V, Bright Singh IS, Narayanan RB, Expression profile of key immune-related genes in *Penaeus monodon* juveniles after oral administration of recombinant envelope protein VP28 of white spot syndrome virus, *Microbial Pathogenesis* (2016), doi: [10.1016/j.micpath.2016.05.002](https://doi.org/10.1016/j.micpath.2016.05.002).

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.





1 **Expression profile of key immune-related genes in *Penaeus monodon* juveniles after oral**
2 **administration of recombinant envelope protein VP28 of White Spot Syndrome Virus**

3 Ancy Thomas¹, Naduvilamuriparampu Saidumammed Sudheer², Viswanath Kiron³, Issac
4 S Bright Singh², Rangarajan Badri Narayanan^{1*}

5 ¹ Centre for Biotechnology, Anna University, Chennai, India

6 E-Mails: anci.thomas@gmail.com, rbn@annauniv.edu

7 ² National Centre for Aquatic Animal Health, Cochin University of Science and Technology,
8 Cochin, India

9 E-Mails: cusatmarine@gmail.com, isbsingh@gmail.com

10 ³ Faculty of Biosciences and Aquaculture, University of Nordland, 8049 - Bodø, Norway

11 E-Mail: kiron.viswanath@hibo.no

12 **Abstract**

13 White spot syndrome virus (WSSV) is the most catastrophic pathogen the shrimp
14 industry has ever encountered. VP28, the abundant envelope protein of WSSV was expressed
15 in bacteria, the purified protein administered orally to *Penaeus monodon* juveniles and its
16 immune modulatory effects examined. The results indicated significant up-regulation of
17 caspase, penaeidin, crustin, astakine, syntenin, PmRACK, Rab7, STAT and C-type lectin in
18 animals orally administered with this antigen. This revealed the immune modulations in
19 shrimps followed by oral administration of rVP28P which resulted in the reduced
20 transcription of viral gene *vp28* and delay in mortality after WSSV challenge. The study
21 suggests the potential of rVP28P to elicit a non-specific immune stimulation in shrimps.

22 **1. Introduction**

23 Penaeid shrimp, one of the most economically important crustaceans, faces significant
24 outbreaks of many diseases that have damaged aquaculture. White spot syndrome virus
25 (WSSV) is the most catastrophic pathogen the shrimp industry has ever encountered [1,2].
26 Since the first report of WSSV in 1993, the major concern of world aquaculture industry has
27 been to stave off this disease emerging in aquaculture settings [3]. There is increasing
28 evidence based on laboratory trials that the administration of antigens or immunostimulants is

29 a promising approach to stimulate shrimp immune system against viral or bacterial infections.
30 Administration of inactivated whole virus, oral recombinant protein antigens and DNA and
31 dsRNA molecules provides remarkable protection to shrimp from WSSV as reviewed by
32 Rowley and Pope [4] and Haq et al. [5].

33 Several investigations suggest that the administration of recombinant WSSV proteins,
34 particularly VP28, imparts a form of immune stimulation, described as immune priming,
35 resulting in increased survival of shrimps in subsequent virus infections [6]. VP28 is the
36 major envelope protein of WSSV that expedites entry of the virion into shrimp cells [7]. The
37 mRNA transcription of WSSV genes was delayed for 4~10 days in various organs of shrimp
38 vaccinated with recombinant VP28 (rVP28) [8]. However, the underlying mechanism by
39 which rVP28 activates the shrimp defense system remains unknown.

40 The crustacean immune system eliminates pathogens very efficiently through humoral
41 and cellular immune processes. The biological defense molecules produced in shrimps in
42 response to the invading pathogens include proteins and peptides related to immunity,
43 homeostasis, host pathogen interaction and other cellular processes. Identification and
44 functional analysis of immune related genes such as AMPs, proteinases and their inhibitors,
45 anti-apoptotic proteins, pattern recognition receptors (PRRs) revealed its specific roles in
46 shrimp defense system and in disease process [9]. Shrimps evolved to use diverse
47 antimicrobial peptides (AMPs) and proteins with diversity in structure and function as the
48 first-line of innate immune response [10]. The identification of thousands of high quality
49 Expressed Sequence Tags (EST) in shrimps suggested that WSSV infection modulates the
50 genes involved in several cellular and metabolic immune processes in post larvae [11].
51 Administration of immune stimulants alters the expression of wide range of cellular and
52 immune related genes and triggers the innate immune reactions in shrimps by upregulation of
53 penaeidin, lysozyme, crustin and JAK-STAT pathway genes and downregulation of AMPs
54 and clotting related proteins in WSSV resistant animals [12,13].

55 The high frequency of occurrence and differential expression of immune-related
56 genes in shrimps infected with WSSV, *Vibrio harveyi* or administered with probiotics further
57 emphasize the molecular changes during an elevated immune response [14,15]. Earlier
58 reports also demonstrated enhanced expression of few immune-related genes upon VP28
59 based DNA vaccination [16,17]. However, immune modulations at molecular level upon
60 VP28 administration in shrimps [6] is scanty, which point to the relevance of the present
61 study. Genes associated with immune functions such as pathogen recognition, clotting,

62 melanisation, agglutination, apoptosis, proPO pathway and signal transduction are
63 characterized in shrimps. In the present study, expression of genes associated with these
64 immune processes such as caspase, penaeidin, crustin, astakine, syntenin, *P. monodon*
65 activated protein kinase C (PmRACK), Rab7 receptor, signal transducer and activator of
66 transcription (STAT), superoxide dismutase (SOD), toll like receptor (TLR) and C-type lectin
67 are assessed. We investigated the immune modulation in *P. monodon* juveniles (PL 40) after
68 oral administration of rVP28P and assessed the survival rate of animals challenged with
69 WSSV.

70 **2. Materials and Methods**

71 **2.1 Expression and purification of WSSV VP28 from Indian WSSV isolate**

72 The VP28 gene (*vp28*) identified from an Indian WSSV isolate was retrieved from
73 Genbank (AY422228.1), and putative trans-membrane regions of VP28 were predicted by
74 using TMpred (http://www.ch.embnet.org/software/TMPRED_form.html) (Data not shown).
75 Expression construct of VP28 was generated in fusion with His6X tag. The full length ORF
76 of 612 bp (VP28) and a truncated form of 546 bp (VP28P) without N-terminal
77 transmembrane region (amino acids 1-22) were PCR amplified. Gene specific primers
78 carrying BamHI and NotI restriction sites were used for the amplification of the insert
79 sequences from TOPO vector and cloned into pET28a⁺ expression vector (Novagen,
80 Madison, Wisconsin, USA). Transformation and expression of rVP28 and rVP28P were
81 achieved in *E. coli* BL21 (Invitrogen, Carlsbad, MA, USA). Their over expression in *E. coli*
82 was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
83 and western blot using 6X Histidine specific monoclonal antibody (1:20000; Genei,
84 Bangalore, India).

85 The rVP28 and rVP28P expressed *E. coli* BL21 cultures were re-suspended in binding
86 buffer (50 mM NaH₂PO₄, 20 mM Tris, 100 mM NaCl) and sonicated. As the full length
87 rVP28 accumulated as inclusion bodies, rVP28P available in the soluble form was selected
88 for further purification by immobilized metal affinity chromatography (IMAC). The total cell
89 lysate was loaded onto Ni-Sepharose column and gradient elution was carried out by adding
90 imidazole at concentrations of 50–500 mM after incubation for 3 hr. The purified rVP28P
91 was concentrated by ultrafiltration (Amicon Ultra 15, Millipore, MA, USA), dialyzed and,

92 assessed for the presence of bacterial endo-toxin using Limulus Amebocyte Lysate (LAL)
93 assay as per manufacturer's (E-Toxate Kit, Sigma, St. Louis, MO, USA) protocol.

94 **2.2 Oral administration of rVP28P to *P. monodon* juveniles and WSSV challenge**

95 2.2.1 Experimental animals

96 Specific Pathogen Free (SPF) *P. monodon* juveniles (PL 40) maintained in a
97 recirculating aquaculture system developed by National Centre for Aquatic Animal Health,
98 Cochin University of Science and Technology, Cochin, Kerala, India was used for the study.
99 The WSSV-free status of animals was tested by nested PCR as described by Lo et al. [18]
100 using viral DNA extracted from whole animal. The shrimps were transferred to rectangular
101 fiber reinforced plastic (FRP) tanks of 30 litre capacity prior to the experiment and
102 acclimatized to 20 g L⁻¹ salinity filtered sea water at 28 ± 1 °C, having total ammonia < 0.1
103 ppm, alkalinity 70-80 ppm at pH 8.4, for one week. The animals were maintained at this
104 optimum conditions through partial exchange of water whenever required. During this period,
105 shrimps were fed with a commercial feed (Amalgam Nutrients and Feeds Limited, Cochin,
106 India) at the rate of 10% body weight per day.

107 2.2.2 Preparation of rVP28P protein coated feed

108 rVP28P was produced in large scale and a quantity of 100 µg purified rVP28P
109 blended with 1ml phosphate buffered saline (PBS-pH 7.4). This was mixed with 4 g (at the
110 rate of 25 µg protein g⁻¹ feed) commercial shrimp feed pellets (Amalgam Nutrients and
111 Feeds Limited, Cochin, India) and incubated overnight at 4 °C to allow the absorption of
112 protein. The pellets were further coated with a commercial binder (Trubind, Wockhardt,
113 Mumbai, India) to prevent dispersion of the protein in water and maintained at 4 °C.
114 Similarly, control feed was prepared by soaking in PBS and coating with the same
115 commercial binder.

116 2.2.3 Oral administration of rVP28P and WSSV challenge

117 Four groups of animals (groups of 125) each animal weighing 2-4 g were used for the
118 experiment and the design was as shown in Table 1. Feed mixed with PBS alone was
119 administered to two batches of animals (PBS 1 and PBS 2) and maintained as controls and
120 two batches administered with rVP28P in PBS (rVP28P 1 and rVP28P 2) served as the tests.
121 All the animals were starved for 6 hr and offered PBS and rVP28P dissolved in PBS as

122 control and test feeds respectively. The feeding rate was of 10% of the body weight twice a
123 day for a period of ten days and thereafter, resorted to normal commercial feed. On 1st day
124 post administration of the coated feed, a batch of rVP28P (rVP28P 2) and PBS administered
125 (PBS 2) animals were challenged with WSSV by feeding freshly infected tissue (soft tissue
126 from cephalothorax confirmed WSSV positive through nested PCR) at a rate 10% of the body
127 weight [19]. The uneaten WSSV infected tissue pieces were removed from the tanks after 4
128 hours of feeding along with complete replacement of water with fresh sea water. The
129 percentage survival of the rVP28P administered animals at the event of challenge with WSSV
130 compared with that in the control group was recorded.

131 **2.3 Tissue sampling, RNA extraction and cDNA synthesis**

132 Animals survived were collected from unchallenged and WSSV challenged groups on
133 2nd, 5th and 8th days post administration (dpa) and post challenge (dpc) respectively. Three
134 batches of animals comprising three animals each from each group were collected from tests
135 and controls, euthanized by immersing in ice flakes, washed with diethyl pyrocarbonate
136 (DEPC) treated water, preserved in Tri- Reagent (Sigma, USA) and maintained at -80 °C.
137 Total RNA was extracted individually from each whole animal of all experimental groups and
138 converted to cDNA within 12 hr of collection of samples under RNase free condition. The
139 total RNA was isolated using TRI reagent (Sigma, St. Louis, MO, USA) following
140 manufacturer's protocol with slight modifications. Briefly, the samples were homogenized
141 and 200 µL chloroform was added per ml of TRI reagent. The RNA was precipitated with
142 70% isopropyl alcohol, dissolved in 20 µL RNase free water followed by DNase I treatment
143 at 37 °C. Further, the quality and quantity of RNA was determined using UV-visible
144 spectrophotometer and confirmed using Qubit RNA assay kit (Life technologies, USA). RNA
145 was subjected to electrophoresis on denaturing gel (5% polyacrylamide gel in Tris -borate
146 EDTA (TBE buffer) containing 7 M urea) to assess the integrity of RNA. Immediately after
147 RNA extraction, 5 µg RNA was reverse transcribed to cDNA using Moloney Murine
148 Leukemia Virus (M-MuLV) Reverse Transcriptase and oligo dT₍₁₂₋₁₈₎ (New England Biolabs,
149 MA, USA) as per the standard protocol and the quality and quantity of cDNA were also
150 assessed spectrophotometrically.

151 **2.4 Expression of immune-related genes upon rVP28P administration - semi** 152 **quantitative reverse transcriptase - polymerase chain reaction (RT-PCR)**

153 All extracted RNA samples had Abs₂₆₀/Abs₂₈₀ ratio of 1.8-2.0 in water and were used
154 for cDNA preparation from 5 µg of total RNA. The 25 µL PCR mixture with 200 µM dNTPs,
155 10 pmol each forward and reverse primers, 1 X PCR buffer (Thermopol), 0.5 U Taq DNA
156 Polymerase and 1 µL cDNA each were used. The cycle parameters were initial denaturation
157 at 94 °C for 5 min, 25-30 cycles of 94 °C for 30 s, annealing for 30 s, extension for 1 min at
158 72 °C and a final extension at 72 °C for 10 min. The PCR cycles and the cDNA dilution had
159 been optimized so that the target gene and reference gene amplification could be obtained at
160 logarithmic phase. In order to check the consistency, the reactions were repeated three times
161 for each gene per sample. The target gene, predicted amplicon size, cycling conditions and
162 primer sequences for each target gene and its source are presented in Table 2.

163 Shrimp elongation factor-5A (EF-5A) was used as the reference gene based on its
164 consistency in the previous experiments. The PCR products were analyzed by horizontal gel
165 electrophoresis and the average integrated density values (IDV) of the amplicons were semi-
166 quantitatively measured using Quantity One[®] software (Bio-Rad, Philadelphia, USA) and
167 normalized with the expression of EF-5A.

168 2.5 Statistics

169 Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software
170 Inc., San Diego, USA). The amplification plots were constructed and represented as mean ±
171 standard deviation of the IDV. Differences between the gene expression of the unvaccinated
172 and rVP28P vaccinated animals at three time points were calculated using non-parametric t-
173 test having $p \leq 0.05$ considered significant. Mean values of target gene expression in three
174 samples, normalized with the expression of the reference gene EF-5A are presented.

175 3. Results

176 3.1 Expression and purification of rVP28P

177 The WSSV *vp28* gene was cloned and expressed in *E. coli* BL21. The VP28 protein
178 sequence contained N-terminus hydrophobic membrane anchoring domain at amino acids 1-
179 22, as elucidated by TMpred (Data not shown). The full length ORF rVP28 (612bp) and a
180 partial reading frame VP28P (546 bp) were expressed in bacteria using pET28a expression
181 system. Bands corresponding to 27 kDa and 25 kDa of full length and truncated protein
182 respectively were visualized in an SDS-PAGE stained with Coomassie Blue G-250 (Fig.1a).
183 The truncated rVP28P expressed in large quantity as soluble protein was further purified

184 using Ni-NTA affinity chromatography, and eluted in 250 mM imidazole (Fig.1b). The
185 purified and dialyzed rVP28P exhibited reactivity with antibodies to His6X (Fig.2a). The
186 endotoxin level in the purified rVP28P was negligible (<1pg/ml of lipopolysaccharide) as
187 determined by LAL assay.

188 **3.2 Oral administration of rVP28P and WSSV challenge**

189 The animals used in the study had been confirmed WSSV free through two step
190 nested PCR for virus detection prior to the experiment. The rVP28P administered and
191 unchallenged animals did not show any sign of infection. Expression of *vp28* was
192 significantly low in rVP28P administered animals on 2nd and 8th dpc compared to the control
193 group (Fig.2b). The reduced expression of *vp28* indirectly evidenced the low proliferation of
194 WSSV in the rVP28P administered shrimps.

195 **3.3 Expression of immune-genes in shrimps administered with rVP28P**

196 Shrimps were orally administered with rVP28P for 10 days and expression of selected
197 immune genes assayed, which indicated the effect of this antigen in the immune system. The
198 statistically significant ($p < 0.05$) up and down regulations when compared with the PBS
199 control group at each time point alone have been brought under this section. Accordingly,
200 caspase transcripts were found up-regulated in the rVP28P administered animals on 2nd dpa.
201 However, it was low in both administered and non-administered groups on 5th and 8th dpa.
202 (Fig.3a). Crustin was up-regulated in the rVP28P administered group on 8th dpa (Fig. 3b).
203 Expression of penaeidin was high on 2nd dpa without any variations on other two time points,
204 as shown in Fig. 3c. Peneidin transcripts were up regulated in rVP28P administered group on
205 2nd dpa compared with that of the control group (Fig. 3c). Astakine was up regulated on 8th
206 day in the rVP28P administered group (Fig. 3d). Up regulation of syntenin on 5th and 8th dpa
207 in the rVP28P administered groups is shown in Figs 3e. A significant upregulation of
208 PmRACK was noticed on 2nd dpa. PmRab7 transcripts were up-regulated on 5th and 8th dpa (p
209 < 0.05) (Fig. 4a). STAT expression was high on 8th dpa (Fig. 4b). Low level expression of
210 TLR was observed on 8th dpa compared with that of the control (Fig. 4c). C-type lectin
211 exhibited up-regulation on 8th dpa in the rVP28P administered animals (Fig. 4d) with no
212 variation between administered and control groups at any time points.

213 Among the seven immune-related genes analyzed, caspase, penaeidin, crustin,
214 astakine, syntenin, PmRACK, Rab7, STAT and C-type lectin transcripts exhibited up-

215 regulation after rVP28P administration at least at one-time point, whereas TLR was down-
216 regulated.

217 **3.4 Time - mortality relationship of animals after rVP28P administration and WSSV** 218 **challenge**

219 In the survival analysis, rVP28P administered animals exhibited delayed mortality
220 compared to the PBS administered group (positive) which exhibited 100% mortality on 10th
221 dpc. The unchallenged animals (negative) exhibited no mortality (Fig. 5).

222 **4. Discussion**

223 In the present study, we conducted an investigation of the gene expression pattern in
224 the rVP28P immunized shrimps using the whole animal (*P. monodon* juveniles) instead of
225 specific shrimp tissue or organ. WSSV is systemic and infects ectodermal and mesodermal
226 originated tissues and organs of shrimps and the immune response vary among different
227 tissues and organs [20]. In different cell types, the virus is likely to modulate the gene
228 expression differently in order to promote its multiplication. Therefore, the assessment of
229 immune molecules in whole animal reveals the overall molecular changes which might be
230 underlying rVP28P mediated protective immunity in shrimps.

231 *E. coli* based protein expression system yields the highest quantity of rVP28P from a
232 given biomass. The expression analysis of full-length and truncated VP28 in *E. coli* indicates
233 higher level of soluble expression of the latter while the former accumulated as inclusion
234 bodies. The high yield and solubility of rVP28P aids large scale production for commercial
235 purposes, and may enhance the bioavailability and absorption of the protein in the gut of the
236 animal after oral administration. The high solubility of rVP28P also facilitates its purification
237 in non-denaturant condition.

238 Despite several reports demonstrating the efficacy of crude rVP28 against WSSV [6],
239 we used purified rVP28P, which was tested endotoxin-free. This facilitated the assessment of
240 immune responses highly specific to the WSSV antigen VP28.

241 The expression of WSSV gene *vp28* transcripts correlated with the WSSV
242 proliferation and immune-related gene expression indirectly. Transcriptional analysis of
243 WSSV genes, particularly *vp28*, is a well-known approach to assess the viral replication after

244 rVP28 administration [8]. Silencing studies of *vp28* gene further demonstrated its vital role in
245 WSSV replication [21].

246 The expression of caspase in rVP28P administered shrimps was upregulated on the
247 2nd dpa compared with PBS control. This may indicate the immediate activation of caspase
248 by the oral administration of rVP28P. Suppression of caspase gene in *M. japonicas* prior to
249 WSSV invasion led to inhibition of apoptosis and increase in WSSV copy number [22]. The
250 role of caspase in anti-WSSV immunity is also evident from the high expression of caspase in
251 shrimps infected with WSSV [23, 24]. In the present study, the high level expression of
252 caspase only on 2nd dpa indicates that the antigen administration needs further optimization to
253 maintain the enhanced expression in the rVP28P administered animals to provide prolonged
254 protection. The enhanced and prolonged caspase expression through rVP28P vaccination may
255 help the animals to resist subsequent WSSV infections.

256 The significant upregulation of crustin on 5th and 8th dpa in vaccinated animals when
257 compared with the PBS control group indicates the efficacy of rVP28P as a candidate
258 antigen to stimulate immune system. This can be further correlated with the reduced viral
259 load in the vaccinated animals as evidenced from the low gene expression of *vp28*. Crustin-
260 like AMPs were found to be constitutively expressed in shrimps and upregulated after the
261 administration of immune stimulants and WSSV challenge [25]. The significant increase of
262 crustin in the vaccinated animals indicates the effect of rVP28P vaccination in the shrimp
263 immune system by increasing the expression of AMPs.

264 The recombinant vaccine administration significantly enhanced the expression of
265 penaeidin on 2nd dpa. This peptide is constitutively synthesized and released into plasma after
266 microbial challenge [26] and, upregulated during *Vibrio* infection in post larvae [27]. These
267 studies demonstrated its role in shrimp host defense and rVP28P mediated protective
268 immunity.

269 In crayfish, *Pacifastacus leniusculus*, hematopoiesis is regulated by an invertebrate
270 cytokine astakine, critical for hemocyte count [28]. The enhanced expression of astakine after
271 rVP28P vaccination in the test animals can positively elevate the hemocyte count and
272 improve the immune status. The high levels of astakine may also contribute to the low
273 expression of *vp28* in the vaccinated animals after WSSV challenge.

274 Syntenin is an adaptor protein that links various molecules in signal transduction
275 pathway. Previous studies reported enhanced expression of syntenin in WSSV infected
276 shrimps which declined rapidly as the infection progressed. This implied the role of syntenin
277 as an important molecule in shrimp immune response subsequent to viral infection [29]. In
278 the present study syntenin levels were significantly higher in rVP28P administered animals
279 on 5th and 8th days after rVP28P administration. The stable maintenance of high levels of
280 syntenin in the animals could attribute to the reduced severity of infection and may offer
281 protection against subsequent viral attacks.

282 PmRACK-1 was elevated in the rVP28P administered animals at all the three time
283 points compared with its PBS control with a significant upregulation on 2nd dpa. This kinase
284 receptor interacts with the VP9 viral protein of WSSV and involves in the response against
285 viral infection in *P. monodon* [30]. It can also participate in the shrimp antioxidant response
286 induced by the formation of ROS [31]. This postulates the rVP28P binding mediated signal
287 transduction activation of the kinase receptor and its role in vaccination mediated protective
288 immunity in shrimps.

289 Rab7 is a VP28 binding protein that aids the recognition and entry of WSSV into
290 shrimp cells. The real-time PCR analysis demonstrated that PmRab7 transcripts were
291 constitutively expressed during the course of WSSV infection and PmRab7-VP28 binding
292 reduces the severity of infection [32]. The enhanced expression of Rab7 on 5th and 8th dpa in
293 the rVP28P vaccinated shrimps implies that rVP28P immunization may aid the neutralization
294 of WSSV in the future viral exposures through Rab7-VP28 interaction and successive
295 immune activation.

296 The significantly increased expression of STAT gene on 8th dpa may help the immune
297 system to respond to a later infection through some unknown STAT-mediated immune
298 mechanism. WSSV uses shrimp STAT as transcription factor to enhance viral gene expression
299 [33]. Here, an increase in STAT gene expression correlates with reduced copies of *vp28*
300 transcripts after WSSV challenge. The STAT-mediated immune activation may reduce the
301 expression of *vp28* and other viral genes thus, negatively affect the WSSV establishment.

302 The innate immune system of shrimps recognizes and binds to specific patterns on the
303 surfaces of pathogens through PRRs [34] and this recognition mechanism and clearance of
304 the pathogen is the supreme part of the shrimp innate immune system. TLR is an important

305 PRR in shrimps that recognize molecules derived from microbes [35]. Down-regulation of
306 TLR in the rVP28P administered animals on 8th dpa evidences to the low significance of TLR
307 mediated immune recognition in this context. C-type lectin is also a major PRR in shrimps
308 and its reduction increases mortality of shrimps during WSSV infection [36]. The significant
309 up-regulation on 8th dpa with rVP28P vaccination may help the animals to resist virus
310 establishment in the future exposures.

311 Time - mortality relationship of shrimps after rVP28P administration and WSSV
312 challenge demonstrated delayed mortality of animals administered with rVP28P. Earlier
313 reports demonstrated the efficacy of VP28 as an oral vaccine which offered more than 60%
314 survival in administered animals [37,38]. In the present study, the oral administration of
315 rVP28P did not show similar trend in survival, except a delay in mortality when compared to
316 that of the controls. More investigations are required to delineate the situation.

317 The present study suggested significant up-regulation of caspase, penaeidin, crustin,
318 astakine, syntenin, PmRACK, Rab7, STAT and C-type lectin in the rVP28P vaccinated
319 animals. This points out the immunomodulation followed by oral administration of rVP28P in
320 *P. monodon* juveniles at molecular level. This resulted in the low expression of viral gene
321 *vp28* and enhanced resistance of shrimps to WSSV and thereby delayed mortality of animals
322 in the subsequent viral challenge. These results are supported by our earlier studies on the
323 modulation of immune-related genes in shrimp juveniles administered with rVP24 [39]. Even
324 though, shrimps lack adaptive immunity and antibodies, investigations on immune
325 modulations and the underlying mechanisms involved, can pave way for a better
326 understanding of how shrimp immune system interacts with pathogen components,
327 particularly rVP28P.

328 The study suggests that rVP28P alone may not protect shrimp from WSSV, and a
329 cocktail of recombinant viral proteins along with immunostimulants might accord protection
330 by enhanced elicitation of non-specific immune mechanism coupled with management of the
331 environment favorable to the animal. The study thus opens up challenging new opportunities
332 for investigation.

333 This work was supported by a grant from the Department of Biotechnology,
334 Government of India, New Delhi, India as a part of Indo - Norwegian program for fish and
335 shellfish vaccine development (BT/AAQ/Indo – Norway/183204/2007).

336

337 **Conflicts of Interest**

338 The authors declare no conflict of interest.

339 **References**

- 340 1) Flegel, T.W.; Major viral diseases of the black tiger prawn *Penaeus monodon* in
341 Thailand. *World. J. Microb. Biot.* 1997, 13(4), 433-442.
- 342 2) Lotz, J.M.; Viruses, biosecurity and specific pathogen-free stocks in shrimp
343 aquaculture. *World. J. Microb. Biot.* 1997, 13(4), 405-413.
- 344 3) Bachère E.; Shrimp immunity and disease control. *Aquaculture.* 2000, 191(1), 3-
345 11.
- 346 4) Rowley, A.F.; Pope, E.C.; Vaccines and crustacean aquaculture—A mechanistic
347 exploration. *Aquaculture.* 2012, 334, 1-11.
- 348 5) Haq, M.A.; Vignesh, R.; & Srinivasan, M.; Deep insight into white spot syndrome
349 virus vaccines: A review. *Asian Pac. J. Trop. Dis.* 2012, 2(1), 73-77.
- 350 6) Mavichaak, R.; Kondo, H.I.D.E.H.I.R.O.; Hirono, I.K.U.O.; & Aoki, T.A.K.A.
351 S.H.I.; The utilization of VP28 gene to protect penaeid shrimps from white spot
352 syndrome virus disease: a review. *Dis. Aqua.* 2011, 7, 157-169.
- 353 7) Tsai, J.M.; Wang H.C.; Leu, J.H.; Wang, A.H.J.Y.; Zhuang, P.J.; Walker, G.H.
354 Kou.; & Lo, C.F.; Identification of the nucleocapsid, tegument, and envelope
355 proteins of the shrimp white spot syndrome virus virion. *J. Virol.* 2006, 80, 3021-
356 3029.
- 357 8) Choi, M.R.; & Jang, J.S.; Transcriptional analysis for oral vaccination of
358 recombinant viral proteins against white spot syndrome virus (WSSV) in
359 *Litopenaeus vannamei*. *J. Microbiol. Biotechnol.* 2011, 21(2), 170-175.
- 360 9) Tassanakajon, A.; Somboonwiwat, K.; Supungul, P.; & Tang, S.; Discovery of
361 immune molecules and their crucial functions in shrimp immunity. *Fish. Shellfish.*
362 *Immun.* 2013, 34(4), 954-967.
- 363 10) Tassanakajon, A.; Amparyup, P.; Somboonwiwat, K.; & Supungul, P.; Cationic
364 antimicrobial peptides in penaeid shrimp. *Mar. Biotechnol.* 2011, 13(4), 639-657.
- 365 11) Leu, J.H., Chang, C.C., Wu, J.L., Hsu, C.W., Hirono, I., Aoki, T., Juan, H.F., Lo,
366 C.F., Kou, G.H. & Huang, H.C.; Comparative analysis of differentially expressed

- 367 genes in normal and white spot syndrome virus infected *Penaeus monodon*. *BMC*
368 *genomics*. 2007, 8(1), 120.
- 369 12) Fagutao, F.F., Yasuike, M., Caipang, C.M., Kondo, H., Hirono, I., Takahashi, Y. &
370 Aoki, T., Gene expression profile of hemocytes of kuruma shrimp, *Marsupenaeus*
371 *japonicus* following peptidoglycan stimulation. *Mar. Biotechnol.* 2008, 10(6),
372 731-740.
- 373 13) Wongpanya, R., Aoki, T., Hirono, I., Yasuike, M. & Tassanakajon, A., Analysis of
374 gene expression in haemocytes of shrimp *Penaeus monodon* challenged with
375 white spot syndrome virus by cDNA microarray. *Sci. Asia*. 2007,33, 165-174.
- 376 14) Pope, E.C.; Powell, A.; Roberts, E.C.; Shields, R.J.; Wardle, R.; & Rowley, A.F.;
377 Enhanced cellular immunity in shrimp *Litopenaeus vannamei* after
378 'vaccination'. *Plos one*. 2011, 6(6), e20960.
- 379 15) Tseng, D.Y.; Ho, P.L.; Huang, S.Y.; Cheng, S.C.; Shiu, Y.L.; Chiu, C.S.; & Liu,
380 C.H.; Enhancement of immunity and disease resistance in the white shrimp,
381 *Litopenaeus vannamei* by the probiotic *Bacillus subtilis* E20. *Fish..Shellfish..*
382 *Immun.*.2009, 26(2), 339-344.
- 383 16) Kono, T.; Fall, J.; Korenaga, H.; Takayama, H.; Iizasa, T.; Mekata, T.; ... & Sakai,
384 M.; Immunomodulation by DNA vaccination against white spot syndrome virus
385 (WSSV). *Asian. Fish. Sci.* 2010, 23, 435-446.
- 386 17) Rajesh Kumar, S.; Ishaq Ahamed, V.P.; Sarathi, M.; Nazeer Basha, A.; & Sahul
387 Hameed, A.S.; Immunological responses of *Penaeus monodon* to DNA vaccine
388 and its efficacy to protect shrimp against white spot syndrome virus
389 (WSSV). *Fish. Shellfish. Immun.* 2008, 24(4), 467-478.
- 390 18) Lo, C.F.; Leu, J.H.; Ho, C.H.; Chen, C.N.; Peng, S.E.; Chen, Y.T. & Kou, G.H.,
391 Detection of baculovirus associated with white spot syndrome (WSBV) in penaeid
392 shrimps using polymerase chain reaction. *Dis. Aquat. Org.* 1996b, 25, 133-141.
- 393 19) Sudheer, N.S.; Philip, R.; & Bright Singh, I.S.; Anti-white spot syndrome virus
394 activity of *Ceriops tagal* aqueous extract in giant tiger shrimp *Penaeus monodon*.
395 *Arch. Virol.* 2012, 157, 1667-1675.
- 396 20) Robalino, J.; Almeida, J. S.; McKillen, D.; Colglazier, J.; Trent III, H. F.; Chen, Y.
397 A.; .. & Gross, P. S.; Insights into the immune transcriptome of the shrimp

- 398 *Litopenaeus vannamei*: tissue-specific expression profiles and transcriptomic
399 responses to immune challenge. *Physiol. genomics*. 2007, 29(1), 44-56.
- 400 21) Sarathi, M.; Simon, M.C.; Venkatesan, C.; & Hameed, A.S.; Oral administration
401 of bacterially expressed VP28dsRNA to protect *Penaeus monodon* from white
402 spot syndrome virus. *Mar. Biotechnol.* 2008, 10(3), 242-249.
- 403 22) Wang, L.; Zhi, B.; Wu, W.; & Zhang, X.; Requirement for shrimp caspase in
404 apoptosis against virus infection. *Dev. Comp. Immunol.* 2008, 32(6), 706-715.
- 405 23) Phongdara, A.; Wanna, W.; & Chotigeat, W.; Molecular cloning and expression of
406 caspase from white shrimp *Penaeus merguensis*. *Aquaculture*. 2006, 252(2), 114-
407 120.
- 408 24) Wongprasert, K.; Sangsuriya, P.; Phongdara, A.; & Senapin, S.; Cloning and
409 characterization of a caspase gene from black tiger shrimp *Penaeus monodon*
410 infected with white spot syndrome virus (WSSV). *J. Biotechnol.* 2007, 131(1), 9-
411 19.
- 412 25) Antony, S. P.; Singh, I. S.; Sudheer, N. S.; Vrinda, S.; Priyaja, P.; & Philip, R.;
413 Molecular characterization of a crustin-like antimicrobial peptide in the giant tiger
414 shrimp, *Penaeus monodon*, and its expression profile in response to various
415 immunostimulants and challenge with WSSV. *Immunobiology*. 2011, 216(1), 184-
416 194.
- 417 26) Destoumieux, D.; Muñoz, M.; Cosseau, C.; Rodriguez, J.; Bulet, P.; Comps, M.' &
418 Bachère, E.; Penaeidins, antimicrobial peptides with chitin-binding activity, are
419 produced and stored in shrimp granulocytes and released after microbial
420 challenge. *J. Cell. Sci.* 2000, 113(3), 461-469.
- 421 27) Nayak, S., Singh, S.K., Ramaiah, N. & Sreepada, R.A.; Identification of
422 upregulated immune-related genes in *Vibrio harveyi* challenged *Penaeus monodon*
423 postlarvae. *Fish. Shellfish. Immun.* 2010, 29(3), 544-549.
- 424 28) Lin, X.; Söderhäll, K.; & Söderhäll, I.; Invertebrate hematopoiesis: an astakine-
425 dependent novel hematopoietic factor. *J. Immunol.* 2011, 186(4), 2073-2079.
- 426 29) Bangrak, P.; Graidist, P.; Chotigeat, W.; Supamattaya, K.; & Phongdara, A.; A
427 syntenin-like protein with postsynaptic density protein (PDZ) domains produced
428 by black tiger shrimp *Penaeus monodon* in response to white spot syndrome virus
429 infection. *Dis. Aquat. Org.* 2002, 49(1), 19-25.

- 430 30) Tonganunt, M.; Saelee, N.; Chotigeat, W.; & Phongdara, A.; Identification of a
431 receptor for activated protein kinase C1 (Pm-RACK1), a cellular gene product
432 from black tiger shrimp (*Penaeus monodon*) interacts with a protein, VP9 from
433 the white spot syndrome virus. *Fish. Shellfish. Immun.* 2009, 26(3), 509-514.
- 434 31) Saelee, N.; Tonganunt-Srithaworn, M.; Wanna, W.; & Phongdara, A.; Receptor for
435 Activated C Kinase-1 protein from *Penaeus monodon* (Pm-RACK1) participates
436 in the shrimp antioxidant response. *Int. J. Biol. Macromol.* 2011, 49(1), 32-36.
- 437 32) Sritunyalucksana, K.; Wannapapho, W.; Lo, C.F.; & Flegel, T.W.; PmRab7 is a
438 VP28-binding protein involved in white spot syndrome virus infection in shrimp.
439 *J. Virol.* 2006, 80, 10734–10742.
- 440 33) Liu, W.J.; Chang, Y.S.; Wang, A.H.J.; Kou, G.H.; & Lo, C.F.; White spot
441 syndrome virus annexes a shrimp STAT to enhance expression of the immediate-
442 early gene ie1. *J. Virol.* 2007, 81(3), 1461-1471.
- 443 34) Vazquez, L.; Alpuche, J.; Maldonado, G.; Agundis, C.; Pereyra-Morales, A.; &
444 Zenteno, E.; Review: immunity mechanisms in crustaceans. *Innate. Immun.* 2009,
445 15(3), 179-188.
- 446 35) Li, F.; & Xiang, J.; Signaling pathways regulating innate immune responses in
447 shrimp. *Fish. Shellfish. Immun.* 2013, 34(4), 973-980.
- 448 36) Ma, T.H.T.; Tiu, S.H.K.; He, J.G.; & Chan, S.M.; Molecular cloning of a C-type
449 lectin (LvLT) from the shrimp *Litopenaeus vannamei*: Early gene down-regulation
450 after WSSV infection. *Fish. Shellfish. Immun.* 2007, 23(2), 430-437.
- 451 37) Witteveldt, J.; Vlak., J.M. & van Hulten, M.C.; Protection of *Penaeus monodon*
452 against white spot syndrome virus using a WSSV subunit vaccine. *Fish Shellfish*
453 *Immun.* 2004a, 16(5), 571-579.
- 454 38) Witteveldt, J.; Cifuentes, C.C.; Vlak, J.M; & van Hulten, M.C. Protection of
455 *Penaeus monodon* against white spot syndrome virus by oral vaccination. *J. Virol.*
456 2004b, 78(4), 2057-2061.
- 457 39) Thomas, A.; Sudheer, N.S.; Viswanathan, K.; Kiron, V.; Singh, I.S.B.; &
458 Narayanan, R.B.; Immunogenicity and protective efficacy of a major White Spot
459 Syndrome Virus (WSSV) envelope protein VP24 expressed in *Escherichia coli*
460 against WSSV. *J. Invertebr. Pathol.* 2014, 123, 17–24.

Table-1 Experimental design for oral administration of rVP28P in *P. monodon* juveniles with timeline of sample collection

Group	Coating material (administered for 10days)	No. of shrimps		Tissue collection
		Unchallenged	WSSV challenged (1dpa)	
PBS 1 (control)	PBS	3x125	-	2 nd , 5 th and 8 th dpa*
PBS 2 (control)	PBS		3x125	2 nd , 5 th and 8 th dpc#
rVP28P 1 (test)	PBS+rVP28P	3x125	-	2 nd , 5 th and 8 th dpa*
rVP28P 2 (test)	PBS+rVP28P		3x125	2 nd , 5 th and 8 th dpc#

dpa - days post administration ; dpc – days post challenge

* Immune gene expression analysis; # WSSV gene *vp28* expression analysis

Table-2 Amplicon size and primers used to amplify WSSV genes and immune-related genes

Target	Amplicon size (bp)	Annealing tem (°C)	Primer sequence	Reference/GenBank Accession Number
EF-5A	737	55	F-5'GCTCTCTCGCTCCTCCTTTCA3' R-5'CCCATGGACAAAGCAAAGG3'	Loongyai et al.,2007
<i>vp28</i>	555	55	F-5'CTGCTGTGATTGCTGTATTT3' R-5'CAGTGCCAGAGTAGGTGAC3'	Liu et al.,2005
Caspase	827	57	F-5'GGAGGAACCTGCGAAGAA3' R-5'AGCGTCGAGTGGATGTAAG3'	Wongprasert et al.,2007

Crustin	430	55	F-5'CGCACAGCCGAGAGAAACACT3' R-5'GGCCTATCCCTCAGAACCCA3,	GQ334395.1
Penaeidin-3	240	55	F-5'AGGATATCATCCAGTTCCTG3' R-5'ACCTACATCCTTTCCACAAG3'	JX961662.1
Astakine	455	56	F-5'GTCGCGCATTTAACAAGGAG3' R-5'CCCTGTGGATTGAGCTCACT3'	EU980446.1
Syntenin	750	55	F-5'GATTTGGCCGTCTCACA3' R-5'GCCTTAAGTTACAGGTCGG3'	AF335106.1
PmRACK-1	937	60	F-5'CTGCGCGGGACCCTGGTG3' R-5'CACGGGAAGTAACGCTGACCT3'	KF041001.1
Rab7	887	55	F-5'TTCCCTCCCAAAGTACAT3' R-5'AGGCCAATCCCCATGTGAA3'	DQ231062.1
STAT	620	55	F-5'AGCCCCTGTCTGAGCGAA3' R-5'CTGAGGCTTCATGAAGTTGG3'	EU367985.1
TLR	670	56	F-5'CTGAGAAACAACAGTTTG3' R-5'GCATTTTGAAATCGAGCG 3'	GU014556.1
C-type lectin	546	57	F-5'CGTGGATCCCAACCTCTTCAGG3' R-5'CGTGAATTCAGCATTGTACTG3'	DQ078266.1

Figure 1





Fig. 1(a) SDS-PAGE of rVP28 and rVP28P expression in *E. coli* BL21. Lane 1-*E. coli* BL21 host induced, Lane 2-pET28a *E. coli* BL21 induced, Lane 3-VP28P pET28a+ uninduced, Lane 4 to 5-rVP28P expressed in *E. coli* BL21, Lane 6- rVP28 expressed in *E. coli* BL21, Lane 7- Protein molecular weight marker (kilodaltons). **1(b)** SDS-PAGE of the purified rVP28P by immobilised metal affinity chromatography. Lane 1-Protein molecular weight marker (kilodaltons), Lane 2-Flow through fraction containing the unbound proteins, Lane 3-Wash fraction that removes all unbound proteins, Lane 4 & 5- Eluted fraction in 100 and 200 mM imidazole fractions, Lane 6-Purified rVP28P eluted in 250 mM imidazole.

Figure 2



2(a) Western blot for the confirmation of expression and purification of rVP28P. Protein resolved in 12% SDS-PAGE gel transferred onto nitrocellulose membrane. Anti-HIS monoclonal antibody (1:20000) was used as primary antibody. Secondary anti mouse antibody-ALP (1:10000) was detected using BCIP-NBT substrates. Lane 1-Protein molecular weight marker (kilodaltons), Lane 2-rVP28P expressed in *E. coli* BL21, Lane 3-rVP28P purified by immobilised metal affinity chromatography. **2(b)** Expression of WSSV gene *vp28* in the rVP28P administered *P. monodon* juveniles compared with the PBS administered group as control. Animals were collected at different time points (2, 5 and 8 day) post challenge and *vp28* transcripts were assessed by semi-quantitative RT-PCR. The expression level in the PBS and rVP28P administered animals were calculated as the mean of the average integrated density values (IDV) of the amplicons relative to the expression reference gene (EF-5A). (* indicates the level of significance; *- $p \leq 0.05$, **- $p \leq 0.01$ & ***- $p \leq 0.001$).

Figure 3




Fig. 3) Expression of immune related genes a) Caspase, b) Crustin, c) Penaeidin, d) Astakine, e) Syntenin and f) PmRACK in rVP28P administered animals compared with the PBS administered group as control on 2nd, 5th and 8th days post administration (dpa) as assessed by semi-quantitative RT-PCR. The expression level was calculated as mean of the average integrated density values (IDV) of the amplicons relative to the expression of reference gene (EF-5A) in the Y-axis and the data are expressed as mean \pm SD of three individual animals. (* indicates the level of significance; *- $p \leq 0.05$, **- $p \leq 0.01$ & ***- $p \leq 0.001$).

Figure 4




Fig. 4) Expression levels of immune related genes a) Rab7, b) STAT, c) TLR and d) C-type lectin in rVP28P administered animals compared with the PBS administered group as control on 2nd, 5th and 8th days post administration (dpa) as assessed by semi-quantitative RT-PCR. The expression level was calculated as mean of the average integrated density values (IDV) of the amplicons relative to the expression of reference gene (EF-5A) in the Y-axis and the data are expressed as mean \pm SD of three individual animals. (* indicates the level of significance; *- $p \leq 0.05$, **- $p \leq 0.01$ & ***- $p \leq 0.001$).


Figure 5

Fig.5) Time-mortality relationship of animals administered with rVP28P after WSSV challenge. Cumulative mortality rates of the *P. monodon* juveniles from the experimental groups, rVP28P administered and challenged as test (VP28), PBS administered and challenged as positive control (positive) and unvaccinated unchallenged as negative control (negative) are plotted against day post challenge. Each experimental group has 3 tanks with 125 animals in each as indicated in the Table 1.

Highlights

- WSSV recombinant envelope protein VP28 was produced as truncated protein and its immune modulatory effects were assessed at molecular level.
- Purified rVP28P was formulated as oral vaccine and administered to shrimp juveniles.
- Up-regulation of syntenin caspase, penaeidin, crustin, astakine, syntenin, PmRACK, Rab7, STAT and C-type lectin after the administration of rVP28P points to the ability of rVP28P to modulate the shrimp immune system.
- Lesser expression of WSSV gene *vp28* in the protein administered animals and delayed mortality of animals in the subsequent viral challenge reveals the efficacy of rVP28P as a vaccine.